1. Media & Marketing

Drug Channels News Roundup, September 2023: PBM Profits, Specialty Rx Markups, CVS Spending Trends, Pharmacy Pricing Secrets, and Deductibles 101

Written by Posted on Less than 0 min read

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch:

  • A must-read report on hidden sources of PBMs’ profits
  • How generic drugs drive specialty pharmacy profits
  • CVS Health’s unadvertised 2022 drug trend report
  • A shocking look at how PBMs set prescription prices

Plus, Dr. Glaucomflecken teaches us about our insurance benefits.

P.S. Join my more than 45,000 LinkedIn followers for daily links to neat stuff. You can also find my daily posts at @DrugChannels on Twitter/X, where I have more than 16,900 followers. (I recommend that you follow me on LinkedIn, because the quality of comments and engagement is much higher than they are on Twitter. I’m not posting to Threads yet.)

Read more »

Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Technology & Innovation

Transforming Medication Access with the Next Generation of Patient Support Services

Today’s guest post comes from Kelly Martin, Vice President of Product Management at CoverMyMeds. Kelly discusses the obstacles that patients face when attempting to access, afford, and adhere to specialty therapies. She describes how CoverMyMeds improves the patient experience by blending technology with human expertise and connection. Click here to learn about CoverMyMed’s next-generation patient […]
2 min read
0
  1. Channel: Drug

What’s Behind CVS Health’s Novel Vertical Integration Strategy for Humira Biosimilars

CVS Health has finally revealed its strategy for biosimilars of AbbVie’s Humira. Rather than announce multiple biosimilars for its pharmacy benefit manager (PBM) formulary, the company will instead launch Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz. Here’s the press release: CVS Health Launches Cordavis. Below, I highlight […]
2 min read
0
  1. Trends & External Forces

Tales of the Unsurprised: U.S. Brand-Name Drug Prices Fell for an Unprecedented Sixth Consecutive Year—And Will Fall Further in 2024 (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. One important update: In the article below, I suggested that the IRA will make high-list/high-rebate products less attractive to Medicare plans. But this appears not be accurate, as I explain in Surprise! […]
3 min read
0
  1. Trends & External Forces

Anti-Obesity Drugs and The Coming Battle Over Utilization Management (video)

My recent Drug Channels Outlook 2024 webinar covered 12 key trends that will shape the commercial environment this year. The video excerpt below highlights my commentary on trend #2: the rapid growth of anti-obesity GLP-1 agonist drugs. As I explain, this growth will challenge payer and channel economics, while boosting profits for patient reimbursement hub […]
2 min read
0
  1. Department: HBC

The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead

Three is still the magic number for pharmacy benefit managers (PBMs). For 2023, nearly 80% of all equivalent prescription claims were processed by three companies: the Caremark business of CVS Health, the Express Scripts business of Cigna, and the Optum Rx business of UnitedHealth Group. Read on for Drug Channels Institute’s (DCI’s) latest market share […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, February 2024: Pharmacy Shakeout Update, High Drug Prices, 340B Realities, MDs vs. Pharmacists, and Foo Fighters

February is longer than usual this year, which means that you’ll have extra time to leap into our monthly curated selection of noteworthy news. In this issue: An update on the retail pharmacy shakeout Arguing for high drug prices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave […]
2 min read
0
  1. Agencies & Vendors

How Prior Auth Solutions Can Empower Patients, Providers and Pharma Field Teams

Today’s guest post comes from Brent Clifton, Vice president of Product Management at CoverMyMeds. Brent discusses the challenges that patients, caregivers, and providers face when seeking access to medications requiring prior authorization. He explains how an electronic prior authorization solution can reduce delays and help patients start their therapies sooner—especially when patients and brands can […]
2 min read
0
  1. Corporate Strategy

Developing a Channel Strategy that Optimizes Gross-to-Net

Today’s guest post comes from Deepak Thomas, Founder and CEO of PHIL Inc. Deepak explains how a manufacturer’s net revenues are affected when that manufacturer helps patients access, afford, and adhere to medication therapy. He provides three suggestions for building a channel strategy to optimize gross-to-net while also improving clinical, financial, and operational outcomes. Click […]
2 min read
0
  1. Trends & External Forces

Drug Channels Outlook 2024 (NEW Live Video Webinar)

It’s time for our most popular event of the year! Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. to […]
3 min read
0
  1. Channel: Drug

CVS, Walgreens, and Walmart Keep Position in 2023 Part D Preferred Networks—While Kroger Bails Over its Express Scripts Blowup (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. One follow-up to this rerun: Kroger’s participation as a preferred pharmacy declined significantly due to its Express Scripts relationship. Based on early 2023 enrollment data, Kroger is preferred in […]
3 min read
0
  1. Department: HBC

The State of Employers’ Pharmacy Benefits: A Review of 2022 and the 2023 Outlook for Copay Programs (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding. Click here to see the original post from January 2023. Now that 2023 is underway, let’s review employer-sponsored coverage for prescription drugs and speculate on what’s ahead. […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, July 2023: GoodRx + CVS Caremark, Accumulators vs. Patients, Hospitals vs. Taxes, and UnitedHealthcare Prior Auth Humor

Let’s cut through the steamy summer haze with Drug Channels’ refreshing breeze of questions for you to ponder while on your favorite pink beach: Why does the biggest PBM need a discount card partner? How do copay accumulators affect prescription adherence? Do nonprofit hospitals deserve their tax exemption? Plus, Dr. Glaucomflecken asks: What would happen […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, February 2022: Mark Cuban vs. PBMs, MDs on Humira Biosimilars, States vs. PBMs, 340B Transparency, and Health Insurer Humor (?)

The era of artificial-intelligence chatbots has arrived! I am pleased to report that this month’s Drug Channels news roundup was most definitely not written by ChatGPT. No promises about future articles. (See our forecast to the right.) In this issue: Mark Cuban explains his anti-PBM strategy What physicians think about Humira biosimilars States go after […]
2 min read
0
  1. Data & Insights

Specialty Treatments in the New Age of Affordability

Today’s guest post is from Divya Iyer, Vice President of Strategy & Business Development, Pharma Manufacturer Solutions, at GoodRx. Divya discusses the challenges patients face in accessing specialty therapies prescribed by their healthcare providers. She suggests how the pharma industry can leverage GoodRx to help patients with access and affordability. Learn more about GoodRx’s insights […]
2 min read
0
  1. Media & Marketing

A Clear Path to Education Affordability Requires Meeting Patients Where They Are

Today’s guest post comes from Kristina Crockett, VP of Product Management at CoverMyMeds. Kristina shares the story of a patient who cut pills in half to extend her prescriptions. Unfortunately, this patient didn’t know about manufacturer affordability programs. In this article, Kristina reviews how brands can help patients make connections that address medication affordability challenges, […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s PAP – Patient Assistance & Access Programs

Informa Connect’s PAP – Patient Assistance & Access Programs March 19-21, 2024 Pre-Conference Workshops on March 18, 2024 Philadelphia Marriott Downtown in Philadelphia, PA Exclusive Offer – Be sure to use your exclusive promo code 24DC10 to save 10% off* of your registration. It is our responsibility as an industry to ensure patients have access […]
4 min read
0
  1. Data & Insights

The 340B Program Climbed to $44 Billion in 2021—With Hospitals Grabbing Most of the Money (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channels Outlook 2023. ICYMI, the Health Resources and Services Administration (HRSA) finally got tired of my Freedom of Information Act (FOIA) requests. Shortly after I published the article below, HRSA posted public data about 340B covered entity purchases on […]
3 min read
0
  1. Trends & External Forces

Available for Preorder: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our fifteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system. This unique, encyclopedic resource is your ultimate guide to the complex web of interactions within […]
3 min read
0
  1. Data & Insights

Surprising Data on Employer-PBM Rebate Pass-Through Arrangements in 2023

Hi, Barbie! The likelihood of major national legislation over the pharmacy benefit management (PBM) industry has never been greater. A serious effort exists to require greater transparency into PBMs’ activities and mandate full pass-through of rebates to plan sponsors. Today, I review some surprising new data on a crucial aspect of the drug channel: how […]
2 min read
0
  1. Media & Marketing

A Reality Check on That Blue Shield of California Announcement

Last week, Anna Matthews of The Wall Street Journal scored a market-moving scoop with her story about Blue Shield of California’s decision to ditch CVS Health’s Caremark pharmacy benefit manager (PBM) in favor of five separate vendors. ICYMI: A Big Health Insurer Is Ripping Up the Playbook on Drug Pricing I commend Blue Shield of […]
2 min read
0
Next